### ü´Ä Atrial Fibrillation: Stroke Prevention Post-Ablation

#### ‚úÖ True Statements
1. **Oral anticoagulation** is indicated for stroke prevention in patients with **nonvalvular atrial fibrillation (AF)** based on **CHA‚ÇÇDS‚ÇÇ-VASc score**.
2. The **CHA‚ÇÇDS‚ÇÇ-VASc score** assigns points for **age ‚â•75 (2 points)**, **female sex**, **hypertension**, and **diabetes**; a total score ‚â•2 in men or ‚â•3 in women warrants anticoagulation.
3. **Catheter ablation** for atrial fibrillation improves symptom control but has **not been shown to reduce stroke risk**, especially in patients at high baseline risk.
4. **Direct oral anticoagulants (DOACs)** such as **apixaban** should be continued in patients with high stroke risk despite ablation.
5. **Left atrial appendage occlusion (LAAO)** is an alternative to anticoagulation only if **oral anticoagulation is not feasible**.
6. Combining **antiplatelet therapy (e.g., aspirin)** with oral anticoagulation increases bleeding risk and is **not recommended** unless there is another clear indication (e.g., recent stenting or stroke).

#### üí¨ Extra
1. Guidelines from the **American College of Cardiology (ACC)**, **American Heart Association (AHA)**, and **Heart Rhythm Society (HRS)** recommend anticoagulation based on CHA‚ÇÇDS‚ÇÇ-VASc scores, with more flexibility now given to consider other factors like chronic kidney disease or arrhythmia burden.
2. This patient's **CHA‚ÇÇDS‚ÇÇ-VASc score of 5** reflects high stroke risk: **2 points for age ‚â•75**, **1 point for hypertension**, **1 for diabetes**, and **1 for female sex**.
3. Discontinuing apixaban post-ablation would be inappropriate given her high stroke risk and lack of contraindications to anticoagulation.

#### üè∑Ô∏è Tags
#Cardiology #AtrialFibrillation #StrokePrevention #CHA2DS2VASc #Apixaban #DOACs #LAAO #CatheterAblation

#### üìö Reference
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol.* 2019;74:104-132. PMID: [30703431](https://pubmed.ncbi.nlm.nih.gov/30703431) doi: [10.1016/j.jacc.2019.01.011](https://doi.org/10.1016/j.jacc.2019.01.011)

#### üÜî Question ID
CVMCQ24116

#### üïí Last Updated
January 2025
